This application claims priority to application Ser. No. 15/060,418 filed Mar. 3, 2016, which is herein incorporated by reference in its entirety.
The instant disclosure relates generally to implants placed within gastrointestinal systems, including the esophagus, the stomach and the intestines. More particularly, it relates to devices and methods for implant systems having components implantable and removable using endoscopic techniques for treatment of obesity, diabetes, reflux, gastroparesis and other gastrointestinal conditions.
Bariatric surgery procedures, such as sleeve gastrectomy, the Roux-en-Y gastric bypass (RYGB) and the bileo-pancreatic diversion (BPD), modify food intake and/or absorption within the gastrointestinal system to effect weight loss in obese patients. These procedures affect metabolic processes within the gastrointestinal system, by either short circuiting certain natural pathways or creating different interactions between the consumed food, the digestive tract, its secretions and the neuro-hormonal system regulating food intake and metabolism. In the last few years there has been a growing clinical consensus that obese patients who undergo bariatric surgery see a remarkable resolution of their type-2 Diabetes Mellitus (T2DM) soon after the procedure. The remarkable resolution of diabetes after RYGB and BPD typically occurs too fast to be accounted for by weight loss alone, suggesting there may be a direct impact on glucose homeostasis. The mechanism of this resolution of T2DM is not well understood, and it is quite likely that multiple mechanisms are involved.
One of the drawbacks of bariatric surgical procedures is that they require fairly invasive surgery with potentially serious complications and long patient recovery periods. In recent years, there has been increased effort to develop minimally invasive procedures to mimic the effects of bariatric surgery. One such procedure involves the use of gastrointestinal implants that modify transport and absorption of food and organ secretions. For example, U.S. Pat. No. 7,476,256 describes an implant having a tubular sleeve with anchoring barbs, which offer the physician limited flexibility and are not readily removable or replaceable. Moreover, stents with active fixation means, such as barbs that deeply penetrate into surrounding tissue, may potentially cause tissue necrosis and erosion of the implants through the tissue, which can lead to complications, such as bacterial infection of the mucosal tissue or systemic infection. Also, due to the intermittent peristaltic motion within the digestive tract, implants such as stents have a tendency to migrate.
Gastroparesis is a chronic, symptomatic disorder of the stomach that is characterized by delayed gastric emptying in the absence of mechanical obstruction. The cause of gastroparesis is unknown, but it may be caused by a disruption of nerve signals to the intestine. The three most common etiologies are diabetes mellitus, idiopathic, and postsurgical. Other causes include medication, Parkinson's disease, collagen vascular disorders, thyroid dysfunction, liver disease, chronic renal insufficiency, and intestinal pseudo-obstruction. The prevalence of diabetic gastroparesis (DGP) appears to be higher in women than in men, for unknown reasons.
Diabetic gastroparesis affects about 40% of patients with type 1 diabetes and up to 30% of patients with type 2 diabetes and especially impacts those with long-standing disease. Both symptomatic and asymptomatic DGP seem to be associated with poor glycemic control by causing a mismatch between the action of insulin (or an oral hypoglycemic drug) and the absorption of nutrients. Treatment of gastroparesis depends on the severity of the symptoms.
Disclosed herein is a gastrointestinal implant for use within a pylorus, a duodenal bulb, and a duodenum of a patient, the implant having an expanded configuration and a contracted configuration and comprising: a proximal portion comprising a hollow tubular braided structure of wire shaped to form a cylinder having a proximal end, a distal end, and a proximal wall extending radially inward from the proximal portion distal end, wherein the proximal wall has an outer circumference and an inner circumference and is configured with a first bias such that the inner circumference is located closer to the proximal portion proximal end than the proximal portion outer circumference; a neck portion comprising a cylinder having a proximal end and a distal end and extending distally from the inner circumference of the proximal portion, the neck portion having a length greater than a width of a pylorus; a distal portion comprising a hollow tubular braided structure of wire shaped to form a cylinder extending distally from the neck portion and having a proximal end, a distal end, and a distal wall extending radially inward from the distal portion proximal end, wherein the distal wall has an outer circumference and an inner circumference and is configured with a second bias such that the inner circumference is located closer to the distal portion distal end than the distal portion outer circumference; and a structural element coupled to the distal portion and configured to resist circumferential compression.
Also disclosed herein is a gastrointestinal device for implanting within a pylorus, a duodenal bulb, and a duodenum of a patient's gastrointestinal tract, the device having a central axis and comprising a first expandable portion comprising a hollow tubular braided structure of wire and having a first cylinder extending parallel to the central axis, the first cylinder having a proximal end, a distal end, and a length and a first face located at the distal end of the first cylinder and oriented transverse to the central axis; a neck portion extending from the first face of the first expandable portion parallel to the central axis, the neck portion having a first end, a second end, a wall extending between the first end and second end, and a diameter sized to fit within a pylorus; and a second expandable portion comprising a hollow tubular braided structure of wire and having a second cylinder extending parallel to the central axis, the second cylinder having a proximal end a distal end and a length and a second face located at the proximal end of the second cylinder and oriented transverse to the central axis wherein the length of the second cylinder is greater than one centimeter.
A gastrointestinal device for implanting within a pylorus, a duodenal bulb, and a duodenum of a patient's gastrointestinal tract, the device comprising a first expandable portion comprising a hollow tubular braided structure of wire shaped to include a disk portion configured to be located on a stomach side of the pylorus; a central cylinder portion having a first end, a second end, and a diameter that fits within the pylorus; a second expandable portion comprising a hollow tubular braided structure of wire shaped to include a cylinder having a proximal end, and distal end, a length between the proximal end and distal end, and a disk portion to be located on an intestinal side of the pylorus, the second expandable portion including a structural element configured to resist circumferential compression; and an intestinal bypass sleeve comprising a sleeve portion, wherein the sleeve portion extends from the duodenal bulb into the duodenum.
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
According to some embodiments, the present disclosure includes an apparatus and method to place and/or anchor a gastrointestinal device within the pyloric antrum, pylorus, duodenum and jejunum. The gastrointestinal device disclosed herein may be implanted by inserting it endoscopically (when the device is loaded into a delivery catheter) through the mouth, throat, stomach and intestines. The gastrointestinal device may include an anchor that can be implanted and remain within a pylorus. The gastrointestinal device may also include an expandable anchor having a flexible thin-walled sleeve attached to the distal end of the anchor. In some embodiments, secondary anchors may also anchor other portions of the thin-walled sleeve.
The instant disclosure may include an expandable anchor that can also be used to hold open the pylorus and may help to reduce the symptoms of gastroparesis by allowing the stomach contents to exit the stomach easier through the pylorus into the duodenum. The instant disclosure may include additional structure, such as an expandable anchor having a short bypass sleeve or no bypass sleeve. In some embodiments, an active pumping means may also be attached to the expandable anchor to actively pump the stomach contents from the pyloric antrum into the duodenum.
The present disclosure is an exemplary version of the apparatus and methods described in U.S. Pat. No. 9,044,300, entitled “Gastrointestinal Prostheses,” granted Jun. 2, 2015, which is incorporated herein by reference. The instant disclosure provides improvements on the performance of previously designed implants. Certain design improvements are generally intended to improve the anchoring performance of the implant and decrease the likelihood that the implant can migrate in response to physiological changes of the body. Additional improvements disclosed herein minimize the likelihood that the sleeve portion of the implant becomes everted or obstructed.
The device 100 as a whole may be alternatively referred to as an implant, an implantable device, a gastrointestinal device, a gastrointestinal implant, or a pyloric implant. The portion of the device 100 that is able to expand and hold the device 100 in place after implantation may be referred to as the anchor, the anchoring portion, the holder, or the holding portion. The sleeve 120 portion of the device 100 that is shown within the small intestine 18 may be alternatively referred to as the sleeve, the intestinal sleeve, the bypass sleeve, the intestinal bypass sleeve, the liner, or the bypass liner. For example, the device 100 may include an intestinal bypass sleeve 120 that is designed to be implanted in the duodenum 26 from the pylorus 20 to the ligament of treitz (not shown). As shown in
According to various embodiments, the sleeve 120, the anchor 110, or both are further coupled at or within the pylorus 20 using one or more of the techniques described in either of U.S. Pat. Nos. 8,211,186 or 8,282,598 filed Jul. 9, 2010, entitled “External Anchoring Configuration for Modular Gastrointestinal Prostheses,” both of which are incorporated herein by reference. According to various embodiments of the invention, the sleeve 120 may be configured to be coupled to the anchor 110, using one or more of the configurations disclosed in U.S. Pat. No. 8,702,641, filed Jan. 7, 2011, entitled “Gastrointestinal Prostheses Having Partial Bypass Configurations,” which is incorporated herein by reference.
In some embodiments, the proximal portion 130 is shaped in a circular or disk shape. In some embodiments, the proximal portion 130 is shaped in a circular or disk shape having a lip or rim. The proximal portion 130 may interchangeably be referred to as a proximal flange. The lip or rim may define a proximal portion proximal end 140 and a proximal portion distal end 142. The lip or rim forming the proximal portion proximal end 140 and the proximal portion distal end 142 may define an overall cylindrical or tubular shape. In some embodiments, the proximal portion 130 circular or disk shape defines a face or wall 148 also referred to herein as the proximal portion wall 148 or proximal flange wall. The proximal flange wall 148 may be a disk that is located on the distal side 142 of the proximal flange 130. The proximal flange wall 148 may be a disk or disk shaped and oriented transverse to the central axis. In general, the proximal end 140 of the proximal portion 130 is open to allow chyme to enter. The distal end 142 of the proximal portion 130 may be connected to the proximal flange wall 148.
In some embodiments, the neck portion 134 defines a through-lumen 152 that allows chyme to flow from the stomach 16 to the small intestine 18. The neck portion 134 may be rigid to hold the pylorus 20 open or it may be compliant to allow the opening and closure of the through lumen 152 with the pylorus 20.
In some embodiments, the distal portion 132 is shaped in a circular or tubular shape. In some embodiments, the distal portion 132 is shaped in a circular, disk, or tubular shape having a lip or rim. The distal portion 132 may interchangeably be referred to as a distal flange. The lip or rim may define a distal portion proximal end 144 and a distal portion distal end 146. The lip or rim forming the distal portion proximal end 144 and the distal portion distal end 146 may define an overall cylindrical or tubular shape. In some embodiments, the distal portion 132 circular or disk shape defines a face or wall 150 also referred to herein as the distal portion wall 150 or distal flange wall. The distal flange wall 150 may be located on the proximal side of the distal flange 132. The distal flange wall 150 may be formed as a disk or disk shaped that is oriented transverse to the central axis. The proximal end 144 of the distal portion 132 may be connected to the distal flange wall 150. In general, the distal portion 132 or distal flange is located in the duodenum and the distal flange 132 has an opening at the distal end 146 that faces the intestine 18.
In some embodiments, the distal flange 132, and the neck portion 134 each form a generally cylindrical shape, each with an independent diameter. For example, the proximal flange 130 has an overall cylindrical shape with an open proximal end 140 having a first diameter, and a distal end 142 having a proximal flange wall 148 that necks down to a diameter of the neck portion 134. The proximal flange wall 148 can be shaped having an angle with a bias in relation to the central axis. The neck portion 134 comprises a cylinder having a second diameter and extends between the proximal flange 130 and the distal flange 132. The distal flange 132 has a generally cylindrical shape and includes the distal flange wall 150 starting from the neck portion 134 and expanding radially from the central axis. The distal flange 132 has a proximal end 144 that is positioned near the pylorus 20, and a distal end 146 that faces into the small intestine 18. The anchor can be oriented by a central axis that is defined as the direction traveling from the proximal flange 130, through the neck portion 134, and continuing through the distal flange 132.
The braided wire structure of the implant may be formed into a shape to promote anchoring to the tissue of a patient. For example, the proximal flange wall 148 and distal flange wall 150 can be angled in relation to the neck portion 134 in order to provide certain spatial relationships to the pylorus 20 at particular locations. In some embodiments, both the proximal flange 130 and distal flange 132 are shaped to apply force F to the proximal and distal face of the pylorus 20, respectively. The effect of this force is intended to keep the implant in place, anchored across the pylorus 20.
The overall length of the anchor 110 can be from about 10.0 mm to about 100.0 mm, but varying sized anchors may be formed, depending on a patient's anatomy or anatomical fit. In some embodiments, the anchor 110 length may be from about 10.0 mm to about 100 mm, from about 25.0 mm to about 75.0 mm, from about 40.0 mm to about 60.0 mm, or any length within these ranges. An exemplary anchor 110 has been formed that is about 50.0 mm long but typical anchors may be in the range of between about 45.0 mm and 55.0 mm. In some embodiments, the diameter of the proximal flange 130 can be from about 10.0 mm to about 75.0 mm, or any range in between, for example from about 25.0 mm to about 60.0 mm, and from about 40.0 mm to about 55.0 mm. An exemplary anchor 110 has been formed with the diameter of the proximal flange 130 about 40.0 mm.
In some embodiments, the distal flange 132 is shaped as a cylinder with a generally open distal end 146 and partially restricted proximal end 144 connected to the distal flange wall 150. The distal flange 132 may be formed in an overall cylindrical shape having a diameter. The length and diameter of the distal flange 132 can be sized to prevent canting or tilting within a tubular anatomical structure such as the duodenum. In some embodiments, the diameter of the distal flange 132 may be from about 5.00 mm to about 60.0 mm, or any range in between, for example from about 20.0 mm to about 50.0 mm, or from about 30.0 mm to about 40.0 mm. For example, the distal flange can have a length of roughly 18.0 mm and a diameter of 35.0 mm, to ensure the structure can remain positioned within a tubular anatomic structure such as the duodenal bulb with a diameter of about 40.0 mm. An exemplary anchor 110 has been formed with the diameter of the distal flange 132 about 35.0 mm in diameter.
As shown in
In some embodiments, the distal flange 132 may have a length that is sized in relation to the length of the proximal flange 130. For example, the length of the distal flange 132 may be the same length as the proximal flange 130. In some embodiments, the length of the distal flange 132 may be multiples of the length of the proximal flange 130. For example, the distal flange 132 may be one and a half, two times, three times, or greater, the length of the proximal flange 130.
In some embodiments, the diameter of the neck portion 134 may be from about 2.0 mm to about 30.0 mm, or any range in between. for example from about 5.00 mm to about 30.0 mm, and from about 10.0 mm to about 20.0 mm. An exemplary anchor 110 has been formed with the diameter of the neck portion 134 about 15.0 mm.
In some embodiments, the length of the neck portion 134 may be approximately the width of a patient's pylorus. In some embodiments, the length of the neck portion 134 may be longer than the width of a patient's pylorus to provide a gap between the proximal flange wall 148 and the distal flange wall 150 and the pylorus 20. In some embodiments, the neck portion 134 may be sized to allow the proximal flange wall 148 and the distal flange wall 150 to contact the pylorus 20. In some embodiments, the anchor 110 is compressible in diameter and the overall diameter can be reduced to about 5.00 to 10.0 mm in diameter typically to allow the anchor 110 to be loaded into a catheter (described further below).
As shown in
The braided structure may be weaved to form a mesh structure 162, and the mesh can be formed into various components. For example, the mesh structure 162 may be formed into disks or cylinders of the various parts of the anchor 110. Suitably sized cylinders may be formed from the mesh structure and may have a diameter from about 10 mm in diameter to about 70 mm in diameter, from about 14 mm to about 50 mm in diameter, and any diameter in between. In some embodiments, a braided structure 160 of different diameters may be used at various locations of the anchor 110. For example, an anchor 110 may be created using a braided structure 160 having a diameter of about 14 mm for the neck portion 134, a braided structure 160 having a diameter of about 34 mm for the distal flange 132, and a braided structure 160 having a diameter of about 40 mm for the proximal flange 130. In exemplary embodiments, the number of wire ends in the braided structure 160 is 96 ends, but it can range from 4 ends to 256 ends. The wire can be formed from a metal such as Nitinol, MP35N, L605, Elgiloy, stainless steel or from a plastic such as Pet, Peek or Delrin or other suitable material.
The anchor 110 can be covered on the outside and/or inside side with a polymer membrane covering. The membrane covering the anchor 110 may be made from a thin-walled polymer material such as silicone, polyurethane, polytetrafluoroethylene, fluorinated ethylene propylene, polyethylene, expanded poly tetrafluoroethylene (ePTFE) or other suitable material. In some embodiments, the wall thickness of the membrane covering the anchor 110 may be in the range of 0.001 inch to 0.030 inch thick. The membrane may be made by extrusion, dip coating from a liquid solution, powder coated from fine particles of polymer or paste extruded and then stretched as is the case with ePTFE. The anchor membrane may also be cut from a flat sheet of material such as ePTFE and then bonded or sewn into a disk shape or spherical shaped structure and then attached to the anchor 110 by sewing or gluing with a polymer such as FEP.
In some embodiments, the anchor 110 also incorporates a structural element contained within the overall structure. Various configurations of the structural element can be found in the following
The structural element 170 can be made from a metal such as Nitinol, MP35N, L605, Elgiloy, stainless steel or from a plastic such as PET, PEEK, or Delrin or other suitable material. In a preferred embodiment, the structural element 170 is made from superelastic Nitinol wire formed into the particular shape. The wire has a diameter from about 0.010 inch to about 0.030 inch, or from about 0.015 inch to about 0.025 inch, or any diameter in between. In one example, a structural element was formed from Nitinol wire having a diameter of about 0.020 inch in diameter. If a structural element having a particular rigidity or stiffness is required, often the size and material that the stiffening element is made from can be used to control these properties. As an example, Nitinol wire has been used to form stiffening elements, which have a compressive and expansive strength that is a function of the diameter of the wire used to make the stiffening element.
In some embodiments, the various components of the anchor 110, including the braided structure 160, the mesh structure 162, the mesh structure with a membrane, and the structural element 170 provide structural support both individually and in combination. The braided structure 160 and mesh structure 162 may contribute support both in a radial and longitudinal direction. The structural element 170 may enhance the overall strength and rigidity of the anchor both in the radial and longitudinal direction. Additionally, the structural element 170 may be tailored to provide a bias to the braided structure 160 and mesh structure 162 to allow the anchor to form a particular shape in response to certain forces. For example, the structural element 170 may add stiffness to the anchor 110 and allow it to maintain an effective circumference. The structural element 170 may provide a compression limit to the anchor 110. The structural element 170 may add longitudinal stability. The structural element 170 may inhibit the anchor 110 from moving through the pylorus.
As shown in
The anchor 110 illustrated in
In the structure illustrated in
In some embodiments, the structural element 190 illustrated in
In some embodiments, such as those shown in
In the embodiments illustrated in
As shown in
The distal structural element 193, 194, 196 may be formed of material having a thickness in the range from 0.010 inch to about 0.040 inch, or any range in between such as from about 0.015 inch to about 0.030, from about 0.020 inch to about 0.025 inch. In an example embodiment, a distal structural element 193, 194, 196 comprised a plurality of rings formed from material having a thickness of about 0.020 inch, or about 0.51 mm. Generally, each of the three rings that form the distal structural element 193, 194, 196 have the same diameter which are in the range of from 1.0 inch to 2.0 inches, and any range within such as from about 1.2 inches to about 1.8 inches, and from about 1.3 inches to about 1.7 inches. In an example embodiment, the distal structural element 193, 194, 196 comprised material formed into rings each having a diameter of about 1.38 inches, or about 35.0 mm.
As shown in
To provide structural support and to optimize the expansive force of the flanges, the orientation of the structural element or rings are arranged to provide any of a static radial force, a static longitudinal force or both. Often this requires the structural element to receive radial support from the neck portion or the wall of the anchor. In some embodiments, such as those shown in
As shown in
As shown in
The proximal structural element 172 may be formed of material having a thickness in the range from 0.015 inch to about 0.045 inch, or any range within such as from about 0.020 inch to about 0.035 inch, from about 0.025 inch to about 0.030 inch. In an example embodiment, a proximal structural element 172 was formed from material having a thickness of about 0.025 inch, or about 0.64 mm.
In some embodiments, attached to the main body 212 of the proximal structural element 172 is a plurality of nodes 204. As shown in
In some embodiments, the anchor 110 may be may be configured to collapse into a narrower size. For example, the anchor 110 may be collapsed into a narrower diameter for placement or removal from a patient.
As shown in
As shown in
The sleeve 120 can vary in length from 1.0-2.0 inches in length up to several feet. In some embodiments, the sleeve 120 bypasses the length of the duodenum up to the ligament of treitz. While various embodiments disclosed herein describe the intestinal bypass sleeve 120 as extending into the duodenum, in all such embodiments, it is also contemplated that the intestinal bypass sleeve 120 has a length sufficient to allow it to extend partially or fully into the jejunum. Often the length of the sleeve is dictated by the required mechanism of action. It has been shown that an effective sleeve length is one that allows it to reach the proximal jejunum; this location corresponds to the location of the ligament of Trietz. The length of the sleeve is determined based on the desired clinical outcome. Recent scientific research has indicated that a sleeve roughly 2 feet in length is sufficient to modify the transport and absorption of food and organ secretions within the small intestine, leading to remission of type 2 diabetes.
The intestinal bypass sleeve 120 may be made from a thin-walled polymer material such as silicone, polyurethane, polytetrafluoroethylene, fluorinated ethylene propylene, polyethylene, expanded polytetrafluoroethylene (ePTFE) or other suitable material. In exemplary embodiments, the wall thickness of the intestinal bypass sleeve 120 may be between 0.0006 inch and 0.010 inch thick. The intestinal bypass sleeve 120 may be made by extrusion, into a tubular form or a lay flat tubing, dip coated from a liquid solution, powder coated from fine particles of polymer or paste extruded and then stretched as is the case with ePTFE.
The gastrointestinal device thus described comprises an anchor configured to be implanted and remain within a pylorus of a patient. The gastrointestinal device may comprise an anchor having a flexible thin-walled sleeve attached to the distal end of the anchor. In some embodiments, secondary anchors may also anchor other portions of the thin-walled sleeve. The anchor may be placed within a pylorus of a patient to assist in opening a pylorus of the patient. The sleeve may be placed within the intestine of the patient and held in place by the anchor. The device thus described may function as follows.
As a person ingests food, the food enters the mouth, is chewed, and then proceeds down the esophagus and into the stomach. The food mixes with enzymes in the mouth and in the stomach. The stomach converts the food to a semi-fluid substance called chyme. The chyme enters the pyloric antrum and exits the stomach through the pylorus. The pylorus (or pyloric sphincter) is a band of muscle that functions to adjust the diameter of the pyloric orifice, which in turn effects the rate at which chyme exits the stomach. The pylorus (or phyloric sphincter or pyloric wall) also has a width (or thickness), which is the distance that the pylorus extends between the stomach and the duodenum.
A gastrointestinal implant placed within the pylorus of a patent can be employed to control the opening and closing of the pylorus to control the flow rate of chyme from the stomach to the intestine of the patient. An exemplary gastrointestinal implant has been formed that can assume both an expanded and contracted configuration. In an exemplary configuration, the implant has a neck portion that allows chyme to flow from the stomach to the intestine of a patient. The width of the neck portion can be designed to control the flow rate of chyme from the stomach to the intestine. The flow rate of chyme can optionally be modified depending on the suitable blood glucose levels of the patient.
The gastrointestinal implant may be held in place within a pylorus of a patient by using an anchor. The anchor comprises a proximal flange and a distal flange connected to the neck portion to anchor the neck portion in place. The proximal flange is configured to remain on the stomach side of a patient's pylorus and the distal flange is configured to remain on the intestinal side of a patient's pylorus. The widths of the proximal flange and distal flange in the expanded configuration are wider than the maximum diameter of the pylorus.
The length of the neck portion can be configured to provide an optimum fit within the pylorus of a patient while preventing the neck portion from agitating the tissue of the pylorus. It has been discovered that an optimum length of the neck portion reduces agitation of the tissue of the pylorus by the anchor by reducing contact between the proximal and distal flanges of the anchor and the pyloric wall. By creating the neck portion to be longer than the width of the pyloric wall, the proximal flange and distal flange are arranged such that they have minimal contact with the pylorus as the pylorus opens and closes. Additionally or alternatively, the shape of the proximal flange and distal flange can be formed to include a bias that reduces contact with the pylorus as the pylorus opens and closes. For example, the proximal flange and distal flange may be formed to provide a space between the proximal flange and distal flange and the pylorus.
The anchor may be formed from material having a hollow tubular braided structure that can assume a collapsed configuration for placement within and removal from a patient's digestive system. The hollow tubular braided structure also can assume an expanded configuration for suitable placement within a patient's digestive track. The anchor may include a structural element that provides additional structural support to the anchor and keeps the anchor in an expanded configuration yet also allows the anchor to be compressed for ease of placement within and extraction from a patient. For example, a structural element can be placed within the distal flange to provide structural support in the radial direction and thus prevent the distal flange from reverting into the stomach of a patient. Additionally or alternatively, a drawstring may be placed within the proximal flange to provide structural support in the radial direction and prevent the proximal flange from traveling into the intestine of a patient. Both the structural elements can be configured to be compressed into a collapsed configuration to allow the anchor to be placed within and removed from within a patient's digestive track. The neck portion of the anchor can be tailored to span the pylorus, and may be tailored to fit various patients of various dimensions. Additionally, the length of the neck portion can be tailored to extend past the pylorus to reduce a compressive force exerted by the flanges onto the pylorus. For example, the length of the neck portion can be designed to sit within the patient's anatomy without continuous contact with the walls of the duodenal bulb and pyloric antrum. The diameter of the neck portion can also be sized to allow food to pass from a patient's stomach to intestine yet remain narrow enough to prevent it from propping open the pylorus.
The small intestine is about 21 feet long in adults. The small intestine is comprised of three sections: the duodenum, jejunum, and ileum. The duodenum is the first portion of the small intestine and is typically 10.0-12.0 inches long. The duodenum is comprised of four sections: the superior, descending, horizontal and ascending. The duodenum ends at the ligament of treitz. The duodenal bulb is the portion of the duodenum which is closest to the stomach. Suitably designed sleeves can be sized wherein the length of the sleeve determines at what point the chyme is allowed to contact the intestine. The design and length of the sleeve also determines at what point food that is traveling through the sleeve comes into contact with digestive juices.
The gastrointestinal implant described here in can be placed within a patient's digestive track by inserting an endoscope through the mouth, esophagus and stomach to the pylorus. An over-the-wire sizing balloon is inserted through the working channel of the endoscope over a guidewire and is advanced across the pyloric opening. The balloon is inflated with saline or contrast media to a low pressure to open the pylorus and duodenum and allow measurement of the lumen diameter of the pyloric antrum, pylorus and duodenal bulb.
In some embodiments, blood glucose levels can be measured by a glucose sensor and the insulin infusion rates and optimum chyme flow rates can be set by the diameter of the neck portion. Currently diabetic patients monitor blood glucose levels and then based on their insulin levels inject themselves with insulin either with a syringe or with an infusion pump. Gastric emptying rates vary depending upon the composition of the food eaten. Sugars pass quickly from the stomach into the small intestine and protein and fats move from the stomach into the small intestine more slowly. Blood sugar control can be difficult to manage if the flow rate of chyme from the stomach to the small intestine is unpredictable and in the case of patients with gastroparesis the chyme flow rate can be very slow to zero. The disclosure herein described will allow for a tighter glucose level control by allowing more precise control of the flow rate of chyme into small intestine and modulating the flow rate of chyme base on blood glucose levels and insulin infusion rate.
Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the above described features.
Number | Name | Date | Kind |
---|---|---|---|
4134405 | Smit | Jan 1979 | A |
4204530 | Finney | May 1980 | A |
4246893 | Berson | Jan 1981 | A |
4314405 | Park | Feb 1982 | A |
4315509 | Smit | Feb 1982 | A |
4416267 | Garren et al. | Nov 1983 | A |
4501264 | Rockey | Feb 1985 | A |
4641653 | Rockey | Feb 1987 | A |
4716900 | Ravo et al. | Jan 1988 | A |
4719916 | Ravo | Jan 1988 | A |
4763653 | Rockey | Aug 1988 | A |
4899747 | Garren et al. | Feb 1990 | A |
4905693 | Ravo | Mar 1990 | A |
5234454 | Bangs | Aug 1993 | A |
5246456 | Wilkinson | Sep 1993 | A |
5306300 | Berry | Apr 1994 | A |
5322697 | Meyer | Jun 1994 | A |
5423872 | Cigaina | Jun 1995 | A |
5474563 | Myler et al. | Dec 1995 | A |
5480423 | Ravenscroft et al. | Jan 1996 | A |
5749921 | Lenker et al. | May 1998 | A |
5753253 | Meyer | May 1998 | A |
5755769 | Richard et al. | May 1998 | A |
5820584 | Crabb | Oct 1998 | A |
6017563 | Knight et al. | Jan 2000 | A |
6224627 | Armstrong et al. | May 2001 | B1 |
6267988 | Meyer | Jul 2001 | B1 |
6454699 | Forsell | Sep 2002 | B1 |
6540789 | Silverman et al. | Apr 2003 | B1 |
6558400 | Deem et al. | May 2003 | B2 |
6675809 | Stack et al. | Jan 2004 | B2 |
6676674 | Dudai | Jan 2004 | B1 |
6740121 | Geitz | May 2004 | B2 |
6755869 | Geitz | Jun 2004 | B2 |
6802868 | Silverman et al. | Oct 2004 | B2 |
6845776 | Stack et al. | Jan 2005 | B2 |
6946002 | Geitz | Sep 2005 | B2 |
6994095 | Burnett | Feb 2006 | B2 |
7025791 | Levine et al. | Apr 2006 | B2 |
7037343 | Imran | May 2006 | B2 |
7037344 | Kagan et al. | May 2006 | B2 |
7044979 | Silverman et al. | May 2006 | B2 |
7090699 | Geitz | Aug 2006 | B2 |
7111627 | Stack et al. | Sep 2006 | B2 |
7121283 | Stack et al. | Oct 2006 | B2 |
7122058 | Levine et al. | Oct 2006 | B2 |
7146984 | Stack et al. | Dec 2006 | B2 |
7152607 | Stack et al. | Dec 2006 | B2 |
7160312 | Saadat | Jan 2007 | B2 |
7163554 | Williams et al. | Jan 2007 | B2 |
7175638 | Gannoe et al. | Feb 2007 | B2 |
7175669 | Geitz | Feb 2007 | B2 |
7211094 | Gannoe et al. | May 2007 | B2 |
7211114 | Bessler et al. | May 2007 | B2 |
7214233 | Gannoe et al. | May 2007 | B2 |
7220237 | Gannoe et al. | May 2007 | B2 |
7220284 | Kagan et al. | May 2007 | B2 |
7223277 | DeLegge | May 2007 | B2 |
7229428 | Gannoe et al. | Jun 2007 | B2 |
7261725 | Binmoeller | Aug 2007 | B2 |
7267694 | Levine et al. | Sep 2007 | B2 |
7288099 | Deem et al. | Oct 2007 | B2 |
7288101 | Deem et al. | Oct 2007 | B2 |
7291160 | DeLegge | Nov 2007 | B2 |
7306614 | Weller et al. | Dec 2007 | B2 |
7314489 | McKenna et al. | Jan 2008 | B2 |
7316716 | Egan | Jan 2008 | B2 |
7329285 | Levine et al. | Feb 2008 | B2 |
7335210 | Smit | Feb 2008 | B2 |
7347875 | Levine et al. | Mar 2008 | B2 |
7354454 | Stack et al. | Apr 2008 | B2 |
7364542 | Jambor et al. | Apr 2008 | B2 |
7364591 | Silverman et al. | Apr 2008 | B2 |
7367937 | Jambor et al. | May 2008 | B2 |
7431725 | Stack et al. | Oct 2008 | B2 |
7476256 | Meade et al. | Jan 2009 | B2 |
7503922 | Deem et al. | Mar 2009 | B2 |
7507218 | Aliski et al. | Mar 2009 | B2 |
7510559 | Deem et al. | Mar 2009 | B2 |
7513914 | Schurr | Apr 2009 | B2 |
7569056 | Cragg et al. | Aug 2009 | B2 |
7601178 | Imran | Oct 2009 | B2 |
7608114 | Levine et al. | Oct 2009 | B2 |
7608578 | Miller | Oct 2009 | B2 |
7618435 | Opolski | Nov 2009 | B2 |
7628821 | Stack et al. | Dec 2009 | B2 |
7678068 | Levine et al. | Mar 2010 | B2 |
7682330 | Meade et al. | Mar 2010 | B2 |
7695446 | Levine et al. | Apr 2010 | B2 |
7758535 | Levine et al. | Jul 2010 | B2 |
7766861 | Levine et al. | Aug 2010 | B2 |
7766973 | Levine et al. | Aug 2010 | B2 |
7815589 | Levine et al. | Oct 2010 | B2 |
7837643 | Levine et al. | Nov 2010 | B2 |
7837669 | Dann et al. | Nov 2010 | B2 |
7935073 | Levine et al. | May 2011 | B2 |
7976488 | Levine et al. | Jul 2011 | B2 |
7981163 | Levine et al. | Jul 2011 | B2 |
8105392 | Durgin | Jan 2012 | B2 |
8114045 | Surti | Feb 2012 | B2 |
8182441 | Swain et al. | May 2012 | B2 |
8211186 | Belhe et al. | Jul 2012 | B2 |
8282598 | Belhe et al. | Oct 2012 | B2 |
8579849 | Grau et al. | Nov 2013 | B2 |
8702641 | Belhe et al. | Apr 2014 | B2 |
8702642 | Belhe et al. | Apr 2014 | B2 |
8882698 | Levine et al. | Nov 2014 | B2 |
9044300 | Belhe et al. | Jun 2015 | B2 |
9173760 | Belhe et al. | Nov 2015 | B2 |
9278019 | Thompson et al. | Mar 2016 | B2 |
20020183768 | Deem et al. | Dec 2002 | A1 |
20020188354 | Peghini | Dec 2002 | A1 |
20030040804 | Stack et al. | Feb 2003 | A1 |
20030040808 | Stack et al. | Feb 2003 | A1 |
20030060894 | Dua et al. | Mar 2003 | A1 |
20030109892 | Deem et al. | Jun 2003 | A1 |
20030109931 | Geitz | Jun 2003 | A1 |
20030109935 | Geitz | Jun 2003 | A1 |
20030120265 | Deem et al. | Jun 2003 | A1 |
20030158601 | Silverman et al. | Aug 2003 | A1 |
20030191476 | Smit | Oct 2003 | A1 |
20030199989 | Stack et al. | Oct 2003 | A1 |
20030199990 | Stack et al. | Oct 2003 | A1 |
20030199991 | Stack et al. | Oct 2003 | A1 |
20040019388 | Starkebaum | Jan 2004 | A1 |
20040024386 | Deem et al. | Feb 2004 | A1 |
20040039452 | Bessler | Feb 2004 | A1 |
20040088022 | Chen | May 2004 | A1 |
20040092892 | Kagan et al. | May 2004 | A1 |
20040093091 | Gannoe et al. | May 2004 | A1 |
20040107004 | Levine et al. | Jun 2004 | A1 |
20040117031 | Stack et al. | Jun 2004 | A1 |
20040122452 | Deem et al. | Jun 2004 | A1 |
20040122453 | Deem et al. | Jun 2004 | A1 |
20040122526 | Imran | Jun 2004 | A1 |
20040133147 | Woo | Jul 2004 | A1 |
20040138760 | Schurr | Jul 2004 | A1 |
20040138761 | Stack et al. | Jul 2004 | A1 |
20040143342 | Stack et al. | Jul 2004 | A1 |
20040148034 | Kagan et al. | Jul 2004 | A1 |
20040158331 | Stack et al. | Aug 2004 | A1 |
20040172141 | Stack et al. | Sep 2004 | A1 |
20040172142 | Stack et al. | Sep 2004 | A1 |
20040172143 | Geitz | Sep 2004 | A1 |
20040199262 | Dua et al. | Oct 2004 | A1 |
20040204768 | Geitz | Oct 2004 | A1 |
20040220682 | Levine et al. | Nov 2004 | A1 |
20040249362 | Levine et al. | Dec 2004 | A1 |
20050004681 | Stack et al. | Jan 2005 | A1 |
20050022827 | Woo et al. | Feb 2005 | A1 |
20050033226 | Kim | Feb 2005 | A1 |
20050033331 | Burnett et al. | Feb 2005 | A1 |
20050043817 | McKenna et al. | Feb 2005 | A1 |
20050049718 | Dann et al. | Mar 2005 | A1 |
20050055039 | Burnett et al. | Mar 2005 | A1 |
20050070934 | Tanaka et al. | Mar 2005 | A1 |
20050075622 | Levine et al. | Apr 2005 | A1 |
20050080395 | Levine et al. | Apr 2005 | A1 |
20050080431 | Levine et al. | Apr 2005 | A1 |
20050080444 | Kraemer et al. | Apr 2005 | A1 |
20050080480 | Bolea et al. | Apr 2005 | A1 |
20050080491 | Levine et al. | Apr 2005 | A1 |
20050085923 | Levine et al. | Apr 2005 | A1 |
20050096673 | Stack et al. | May 2005 | A1 |
20050096750 | Kagan et al. | May 2005 | A1 |
20050125020 | Meade et al. | Jun 2005 | A1 |
20050125075 | Meade et al. | Jun 2005 | A1 |
20050149200 | Silverman et al. | Jul 2005 | A1 |
20050177181 | Kagan et al. | Aug 2005 | A1 |
20050183730 | Byrum | Aug 2005 | A1 |
20050192614 | Binmoeller | Sep 2005 | A1 |
20050197714 | Sayet | Sep 2005 | A1 |
20050228413 | Binmoeller et al. | Oct 2005 | A1 |
20050228504 | Demarais | Oct 2005 | A1 |
20050240279 | Kagan et al. | Oct 2005 | A1 |
20050246037 | Starkebaum | Nov 2005 | A1 |
20050247320 | Stack et al. | Nov 2005 | A1 |
20050250980 | Swanstrom et al. | Nov 2005 | A1 |
20050251157 | Saadat et al. | Nov 2005 | A1 |
20050251206 | Maahs et al. | Nov 2005 | A1 |
20050256587 | Egan | Nov 2005 | A1 |
20050267499 | Stack et al. | Dec 2005 | A1 |
20050273060 | Levy et al. | Dec 2005 | A1 |
20050277963 | Fields | Dec 2005 | A1 |
20050283107 | Kalanovic et al. | Dec 2005 | A1 |
20050288555 | Binmoeller | Dec 2005 | A1 |
20060009858 | Levine et al. | Jan 2006 | A1 |
20060020247 | Kagan et al. | Jan 2006 | A1 |
20060020277 | Gostout et al. | Jan 2006 | A1 |
20060030949 | Geitz | Feb 2006 | A1 |
20060036267 | Saadat et al. | Feb 2006 | A1 |
20060064120 | Levine et al. | Mar 2006 | A1 |
20060155310 | Binmoeller | Jul 2006 | A1 |
20060155312 | Levine et al. | Jul 2006 | A1 |
20060155375 | Kagan et al. | Jul 2006 | A1 |
20060161139 | Levine et al. | Jul 2006 | A1 |
20060161172 | Levine et al. | Jul 2006 | A1 |
20060161187 | Levine et al. | Jul 2006 | A1 |
20060161265 | Levine et al. | Jul 2006 | A1 |
20060178691 | Binmoeller | Aug 2006 | A1 |
20060206063 | Kagan et al. | Sep 2006 | A1 |
20060206064 | Kagan et al. | Sep 2006 | A1 |
20060249165 | Silverman et al. | Nov 2006 | A1 |
20060258906 | Binmoeller | Nov 2006 | A1 |
20060265082 | Meade et al. | Nov 2006 | A1 |
20060282087 | Binmoeller | Dec 2006 | A1 |
20060293742 | Dann et al. | Dec 2006 | A1 |
20070004963 | Benchetrit | Jan 2007 | A1 |
20070005147 | Levine et al. | Jan 2007 | A1 |
20070010794 | Dann et al. | Jan 2007 | A1 |
20070010864 | Dann et al. | Jan 2007 | A1 |
20070010865 | Dann et al. | Jan 2007 | A1 |
20070010866 | Dann et al. | Jan 2007 | A1 |
20070021761 | Phillips | Jan 2007 | A1 |
20070027548 | Levine et al. | Feb 2007 | A1 |
20070032702 | Ortiz | Feb 2007 | A1 |
20070032879 | Levine et al. | Feb 2007 | A1 |
20070038308 | Geitz | Feb 2007 | A1 |
20070060932 | Stack et al. | Mar 2007 | A1 |
20070078302 | Ortiz et al. | Apr 2007 | A1 |
20070083271 | Levine et al. | Apr 2007 | A1 |
20070100367 | Quijano et al. | May 2007 | A1 |
20070118158 | Deem et al. | May 2007 | A1 |
20070118159 | Deem et al. | May 2007 | A1 |
20070135825 | Binmoeller | Jun 2007 | A1 |
20070167963 | Deem et al. | Jul 2007 | A1 |
20070198074 | Dann et al. | Aug 2007 | A1 |
20070203517 | Williams et al. | Aug 2007 | A1 |
20070213740 | Deem et al. | Sep 2007 | A1 |
20070213748 | Deem et al. | Sep 2007 | A1 |
20070213751 | Scirica et al. | Sep 2007 | A1 |
20070213837 | Ferreri et al. | Sep 2007 | A1 |
20070219570 | Deem et al. | Sep 2007 | A1 |
20070239284 | Skerven et al. | Oct 2007 | A1 |
20070250083 | Deem et al. | Oct 2007 | A1 |
20070250132 | Burnett | Oct 2007 | A1 |
20070265709 | Rajan et al. | Nov 2007 | A1 |
20070276432 | Stack et al. | Nov 2007 | A1 |
20070282349 | Deem et al. | Dec 2007 | A1 |
20070282418 | Weitzner | Dec 2007 | A1 |
20070282452 | Weitzner et al. | Dec 2007 | A1 |
20070282453 | Weitzner et al. | Dec 2007 | A1 |
20070282454 | Krueger et al. | Dec 2007 | A1 |
20070293885 | Binmoeller | Dec 2007 | A1 |
20080033574 | Bessler et al. | Feb 2008 | A1 |
20080045803 | Williams et al. | Feb 2008 | A1 |
20080065122 | Stack et al. | Mar 2008 | A1 |
20080065136 | Young | Mar 2008 | A1 |
20080071383 | Levine et al. | Mar 2008 | A1 |
20080086214 | Hardin et al. | Apr 2008 | A1 |
20080092910 | Brooks | Apr 2008 | A1 |
20080097466 | Levine et al. | Apr 2008 | A1 |
20080103604 | Levine et al. | May 2008 | A1 |
20080109086 | Voegele et al. | May 2008 | A1 |
20080109087 | Durgin | May 2008 | A1 |
20080140172 | Carpenter et al. | Jun 2008 | A1 |
20080161935 | Albrecht et al. | Jul 2008 | A1 |
20080167606 | Dann et al. | Jul 2008 | A1 |
20080167610 | Dann et al. | Jul 2008 | A1 |
20080167629 | Dann et al. | Jul 2008 | A1 |
20080167724 | Ruane et al. | Jul 2008 | A1 |
20080183238 | Chen | Jul 2008 | A1 |
20080195225 | Silverman et al. | Aug 2008 | A1 |
20080195226 | Williams et al. | Aug 2008 | A1 |
20080208135 | Annunziata | Aug 2008 | A1 |
20080208161 | Kaji et al. | Aug 2008 | A1 |
20080208224 | Surti et al. | Aug 2008 | A1 |
20080208239 | Annunziata | Aug 2008 | A1 |
20080208355 | Stack et al. | Aug 2008 | A1 |
20080208356 | Stack et al. | Aug 2008 | A1 |
20080208357 | Melanson et al. | Aug 2008 | A1 |
20080221597 | Wallace et al. | Sep 2008 | A1 |
20080221702 | Wallace et al. | Sep 2008 | A1 |
20080234834 | Meade et al. | Sep 2008 | A1 |
20080243151 | Binmoeller et al. | Oct 2008 | A1 |
20080249533 | Godin | Oct 2008 | A1 |
20080249566 | Harris et al. | Oct 2008 | A1 |
20080249635 | Weitzner et al. | Oct 2008 | A1 |
20080255476 | Boyajian et al. | Oct 2008 | A1 |
20080255587 | Cully et al. | Oct 2008 | A1 |
20080255594 | Cully et al. | Oct 2008 | A1 |
20080255678 | Cully et al. | Oct 2008 | A1 |
20080262529 | Jacques | Oct 2008 | A1 |
20080269715 | Faller et al. | Oct 2008 | A1 |
20080269797 | Stack et al. | Oct 2008 | A1 |
20080287969 | Tsonton et al. | Nov 2008 | A1 |
20080312559 | Santilli et al. | Dec 2008 | A1 |
20080319455 | Harris et al. | Dec 2008 | A1 |
20090005637 | Chin et al. | Jan 2009 | A1 |
20090012541 | Dahl et al. | Jan 2009 | A1 |
20090012542 | N'diaye et al. | Jan 2009 | A1 |
20090012544 | Thompson et al. | Jan 2009 | A1 |
20090012553 | Swain et al. | Jan 2009 | A1 |
20090076588 | Weber | Mar 2009 | A1 |
20090093767 | Kelleher | Apr 2009 | A1 |
20090093839 | Kelleher | Apr 2009 | A1 |
20090118749 | Shalon et al. | May 2009 | A1 |
20090125119 | Obermiller et al. | May 2009 | A1 |
20090138094 | Schurr | May 2009 | A1 |
20090149871 | Kagan et al. | Jun 2009 | A9 |
20090164028 | Chen | Jun 2009 | A1 |
20090177215 | Stack et al. | Jul 2009 | A1 |
20090182355 | Levine et al. | Jul 2009 | A1 |
20090187206 | Binmoeller et al. | Jul 2009 | A1 |
20090198210 | Burnett et al. | Aug 2009 | A1 |
20090216262 | Burnett et al. | Aug 2009 | A1 |
20090240105 | Smit et al. | Sep 2009 | A1 |
20090240340 | Levine et al. | Sep 2009 | A1 |
20090248171 | Levine et al. | Oct 2009 | A1 |
20090276055 | Harris et al. | Nov 2009 | A1 |
20090281379 | Binmoeller et al. | Nov 2009 | A1 |
20090299486 | Shohat et al. | Dec 2009 | A1 |
20090299487 | Stack et al. | Dec 2009 | A1 |
20090326433 | Albrecht et al. | Dec 2009 | A1 |
20090326675 | Albrecht et al. | Dec 2009 | A1 |
20100004755 | Imran | Jan 2010 | A1 |
20100016988 | Stack et al. | Jan 2010 | A1 |
20100030017 | Baker et al. | Feb 2010 | A1 |
20100135971 | Schiffrin | Jun 2010 | A1 |
20100256775 | Belhe et al. | Oct 2010 | A1 |
20100305590 | Holmes et al. | Dec 2010 | A1 |
20110009690 | Belhe et al. | Jan 2011 | A1 |
20110106273 | Belhe et al. | May 2011 | A1 |
20120065571 | Thompson et al. | Mar 2012 | A1 |
20120109188 | Viola | May 2012 | A1 |
20120184893 | Thompson et al. | Jul 2012 | A1 |
20120232460 | Raven et al. | Sep 2012 | A1 |
20120253259 | Belhe et al. | Oct 2012 | A1 |
20120253260 | Belhe et al. | Oct 2012 | A1 |
20120302936 | Belhe et al. | Nov 2012 | A1 |
20130030351 | Belhe et al. | Jan 2013 | A1 |
20130324907 | Huntley et al. | Dec 2013 | A1 |
20140194806 | Belhe et al. | Jul 2014 | A1 |
20140200502 | Belhe et al. | Jul 2014 | A1 |
20140309576 | Belhe et al. | Oct 2014 | A1 |
20140350694 | Behan | Nov 2014 | A1 |
20140379093 | Durgin | Dec 2014 | A1 |
20160089256 | Belhe et al. | Mar 2016 | A1 |
20160228276 | Thompson et al. | Aug 2016 | A1 |
Number | Date | Country |
---|---|---|
2006227471 | Sep 2006 | AU |
2014200766 | Jun 2015 | AU |
1575155 | Feb 2005 | CN |
1618411 | May 2005 | CN |
0137878 | Apr 1985 | EP |
1420730 | May 2004 | EP |
1492477 | Jan 2005 | EP |
1492478 | Jan 2005 | EP |
1555970 | Jul 2005 | EP |
1569582 | Sep 2005 | EP |
1585458 | Oct 2005 | EP |
1680054 | Jul 2006 | EP |
1708641 | Oct 2006 | EP |
1708655 | Oct 2006 | EP |
1709508 | Oct 2006 | EP |
1749482 | Feb 2007 | EP |
1750595 | Feb 2007 | EP |
1778069 | May 2007 | EP |
1786310 | May 2007 | EP |
1799145 | Jun 2007 | EP |
1817072 | Aug 2007 | EP |
1832250 | Sep 2007 | EP |
1850811 | Nov 2007 | EP |
1850812 | Nov 2007 | EP |
1881781 | Jan 2008 | EP |
1887995 | Feb 2008 | EP |
1895887 | Mar 2008 | EP |
1937164 | Jul 2008 | EP |
1992314 | Nov 2008 | EP |
1416861 | Dec 2008 | EP |
1749480 | Dec 2008 | EP |
2010270 | Jan 2009 | EP |
1610720 | Feb 2009 | EP |
2023828 | Feb 2009 | EP |
2026713 | Feb 2009 | EP |
2061397 | May 2009 | EP |
2066243 | Jun 2009 | EP |
2068719 | Jun 2009 | EP |
2080242 | Jul 2009 | EP |
1520528 | Sep 2009 | EP |
1610719 | Jan 2010 | EP |
1603488 | Apr 2010 | EP |
1585460 | May 2010 | EP |
1933721 | May 2010 | EP |
1768618 | Apr 2011 | EP |
1883370 | Aug 2011 | EP |
2945566 | Nov 2015 | EP |
2005500127 | Jan 2005 | JP |
2007513684 | May 2007 | JP |
2007513685 | May 2007 | JP |
WO1998049943 | Nov 1998 | WO |
WO2002096327 | Dec 2002 | WO |
WO2003017882 | Mar 2003 | WO |
WO2003086246 | Oct 2003 | WO |
WO2003086247 | Oct 2003 | WO |
WO2003094785 | Nov 2003 | WO |
WO2004011085 | Feb 2004 | WO |
WO2004017863 | Mar 2004 | WO |
WO2004041133 | May 2004 | WO |
WO2004064680 | Aug 2004 | WO |
WO2004064685 | Aug 2004 | WO |
WO2004087014 | Oct 2004 | WO |
WO2004087233 | Oct 2004 | WO |
WO2004049982 | Dec 2004 | WO |
WO2005037152 | Apr 2005 | WO |
WO2005058415 | Jun 2005 | WO |
WO2005060869 | Jul 2005 | WO |
WO2005060882 | Jul 2005 | WO |
WO2005065412 | Jul 2005 | WO |
WO2005097012 | Oct 2005 | WO |
WO2005099591 | Oct 2005 | WO |
WO2005110244 | Nov 2005 | WO |
WO2005110280 | Nov 2005 | WO |
WO2005112822 | Dec 2005 | WO |
WO2005120363 | Dec 2005 | WO |
WO2006014496 | Feb 2006 | WO |
WO2006016894 | Feb 2006 | WO |
WO2006020370 | Feb 2006 | WO |
WO2006028898 | Mar 2006 | WO |
WO2006034062 | Mar 2006 | WO |
WO2006060049 | Jun 2006 | WO |
WO2006062996 | Jun 2006 | WO |
WO2006078781 | Jul 2006 | WO |
WO2006078927 | Jul 2006 | WO |
WO2006102012 | Sep 2006 | WO |
WO2006102240 | Sep 2006 | WO |
WO2006124880 | Nov 2006 | WO |
WO2006127593 | Nov 2006 | WO |
WO2006133311 | Dec 2006 | WO |
WO2007019117 | Feb 2007 | WO |
WO2007030829 | Mar 2007 | WO |
WO2007038715 | Apr 2007 | WO |
WO2007041598 | Apr 2007 | WO |
WO2007075396 | Jul 2007 | WO |
WO2007092390 | Aug 2007 | WO |
WO2007107990 | Sep 2007 | WO |
WO2007127209 | Nov 2007 | WO |
WO2007136468 | Nov 2007 | WO |
WO2007139920 | Dec 2007 | WO |
WO2007142829 | Dec 2007 | WO |
WO2007142832 | Dec 2007 | WO |
WO2007142833 | Dec 2007 | WO |
WO2007142834 | Dec 2007 | WO |
WO2007145684 | Dec 2007 | WO |
WO2008005510 | Jan 2008 | WO |
WO2008030403 | Mar 2008 | WO |
WO2008033409 | Mar 2008 | WO |
WO2008033474 | Mar 2008 | WO |
WO2008039800 | Apr 2008 | WO |
WO2008101048 | Aug 2008 | WO |
WO2008106041 | Sep 2008 | WO |
WO2008106279 | Sep 2008 | WO |
WO2008112942 | Sep 2008 | WO |
WO2008127552 | Oct 2008 | WO |
WO2008141288 | Nov 2008 | WO |
WO2008148047 | Dec 2008 | WO |
WO2008150905 | Dec 2008 | WO |
WO2008154450 | Dec 2008 | WO |
WO2008154594 | Dec 2008 | WO |
WO2009011881 | Jan 2009 | WO |
WO2009011882 | Jan 2009 | WO |
WO2009012335 | Jan 2009 | WO |
WO2009036244 | Mar 2009 | WO |
WO2009046126 | Apr 2009 | WO |
WO2009082710 | Jul 2009 | WO |
WO2009085107 | Jul 2009 | WO |
WO2009086549 | Jul 2009 | WO |
WO2009097582 | Aug 2009 | WO |
WO2009097585 | Aug 2009 | WO |
WO2010115011 | Oct 2010 | WO |
WO2011062882 | May 2011 | WO |
WO2011073970 | Jun 2011 | WO |
WO2011099940 | Aug 2011 | WO |
WO2012103531 | Aug 2012 | WO |
2014113483 | Jul 2014 | WO |
2015138465 | Sep 2015 | WO |
Entry |
---|
International Search Report and Written Opinion issued in PCT/US2017/020494, dated Apr. 3, 2017, 10 pages. |
Buchwald, Henry et al., “Bariatric Surgery: A Systematic Review and Meta-Analysis”, JAMA, Oct. 13, 2004, 292 (14), pp. 1724-1737. |
Cummings, David E. et al., “Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery”, Surgery for Obesity and Related Diseases 3 2007, pp. 109-115. |
Daniels, Stephen, “Probiotics may ‘counter obesity and diabetes’: NIH study”, Jul. 10, 2013, downloaded from http://www.nutraingredients-usa.com/research/probiotics-may-counter-obesity-and-diabetes-NIH-study, 2 pages. |
International Preliminary Report on Patentability issued in PCT/US2014/011702, dated Jul. 30, 2015, 7 pages. |
International Search Report and Written Opinion issued in PCT/US12/58202, dated Jan. 23, 2013, 14 pages. |
International Search Report and Written Opinion issued in PCT/US2010/029648, dated Aug. 24, 2010. |
International Search Report and Written Opinion issued in PCT/US2010/041574, dated Jan. 25, 2011. |
International Search Report and Written Opinion issued in PCT/US2011/020560, dated Mar. 28, 2011, 10 pages. |
International Search Report and Written Opinion issued in PCT/US2011/061193. |
International Search Report and Written Opinion issued in PCT/US2012/023048, dated Jun. 22, 2012. |
International Search Report and Written Opinion issued in PCT/US2014/011702, dated Mar. 21, 2014, 9 pages. |
International Search Report and Written Opinion issued in PCT/US2015/019730, dated Mar. 10, 2015, 15 pages. |
Invitation to Pay Additional Fees issued in PCT/US2010/029648, dated Jun. 1, 2010. |
Ley, Ruth E. et al., “Microbial ecology: human gut microbes associated with obesity”, Nature, vol. 44, No. 7122, pp. 1022-1023, 2006. |
Partial European Search Report issued in EP14172564, dated Feb. 12, 2015 , 7pages. |
Pories, Walter J. et al., “Surgical Treatment of Obesity and its Effect on Diabetes: 10-6 Follow-up”, Am J Clin Nutr 1992, 55, 582S-585S. |
Pories, Walter J. et al., “Who Would Have Thought It? An Operation Proves to be the Most Effective Therapy for Adult-Onset Diabetes Mellitus”, Annals of Surgery, Sep. 1995, 222(3), pp. 339-352. |
Preliminary Report on Patentability issued in PCT/US2015/019730 dated Sep. 22, 2016, 7 pages. |
Rodriguez-Grunert, Leonardo et al., “First Human Experience With endoscopically Delivered and retrieved duodenal-jejunal bypass sleeve”, Surgery for Obesity and Related diseases 4 (2008) 55-59. |
Rubino, Francesco et al,, “Effect of Duodenal-Jejunal Exclusion in a Non-Obese Animal Model of Type 2 Diabetes”, Annals of Surgery, vol. 239, No. 1, Jan. 2004, pp. 1-11. |
Rubino, Francesco et al., “Potential of Surgery for Curing Type 2 Diabetes Mellitus”, Annals of Surgery, Nov. 2002, 236(5), 554-559. |
Rubino, Francesco et al., “The Mechanism of Diabetes Control After Gastrointestinal Bypass Surgery Reveals a Role of the Proximal Small Intestine in the pathophysiology of Type 2 Diabetes”, Annals of Surgery, 244(5), Nov. 2006, pp. 741-749. |
Schouten, Ruben et al., “A Multicenter, Randomized Efficacy Study of the endoBarrier Gastrointestinal Liner for Presurgical Weight Loss Prior to Bariatric Surgery”, Annals of Surgery, vol. 251, No. 2, Feb. 2010, pp. 236-243. |
Strader, April et al., “Weight Loss Through Ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats”, Am J Physiol Endocrinol Metab 288: E447-E453, 2005. |
Supplemental European Search Report issued in EP Application 14740554 dated Sep. 26, 2016, 7 pages. |
Troy, Stephanie et al., “Intestinal Gluconeogenesis is a key factor for early metabolic changes after gastric bypass but not after gastric lap-band in mice”, Cell metabolism 8, 201-211, Sep. 3, 2008. |
U.S. Appl. No. 15/060,418 entitled Pyloric Anchors and Methods for Intestinal Bypass Sleeves filed Mar. 3, 2016. |
Vetter, Marion et al., “Narrative Review: Effect of bariatric Surgery on Type 2 Diabetes Mellitus”, Annals of Internal Medicine, Jan. 20, 2009, 150(2), pp. 94-104. |
Woodard et al., Probiotics Improve Outcomes After Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized Trial, J Gastrointest Surg (2009) 13:1198-1204. |
Yadav, Hariom et al., Beneficial Metabolic Effects of a Probiotic via Butyrate-induced GLP-1 Hormone Secretion, Journal of Biological Chemistry, 2013, vol. 288, pp. 25088-25097. |
Number | Date | Country | |
---|---|---|---|
20170252195 A1 | Sep 2017 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15060418 | Mar 2016 | US |
Child | 15489444 | US |